odanacatib: Clinical Trials

5 trials of odanacatib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 1 terminated. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 4, Terminated 1

Follow odanacatib: new trials by email Literature Review of odanacatib trials Research Report on odanacatib

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Evaluate the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in Postmenopausal Women Previously Treated With a Bisphosphonate (MK-0822-042)
Odanacatib, Placebo, Vitamin D3 - Osteoporosis
Phase 2CompletedMerck Sharp & Dohme LLC2462009-04-132018-08-28
Efficacy and Safety of Odanacatib (MK-0822) in Participants With Involutional Osteoporosis (MK-0822-022)
Odanacatib, Vitamin D3, Calcium carbonate - Osteoporosis Postmenopausal
Phase 2CompletedMerck Sharp & Dohme LLC2872007-12-032018-08-27
A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)
ZA, Odanacatib, Odanacatib matching placebo - Breast Cancer, Metastatic Bone Disease
Phase 2CompletedMerck Sharp & Dohme LLC432006-11-162018-08-16
A 52-Week Study to Assess the Effects of MK0822 on Knee Osteoarthritis (MK-0822-011)
MK0822 - Osteoarthritis
Phase 2TerminatedMerck Sharp & Dohme LLC22006-10-012015-11-02
A Study to Examine the Effects of an Experimental Drug on Postmenopausal Osteoporosis (MK-0822-004)
Odanacatib, Vitamin D3, Calcium Carbonate - Osteoporosis
Phase 2CompletedMerck Sharp & Dohme LLC3992005-06-242018-01-24

Conditions studied

Osteoporosis (2)  ·  Bone Diseases (1)  ·  Breast Neoplasms (1)  ·  Osteoarthritis (1)  ·  Osteoporosis, Postmenopausal (1)

Sponsors

Merck Sharp & Dohme LLC (5)

Countries

Chile (1)  ·  Colombia (1)  ·  Mexico (1)  ·  Poland (1)  ·  United States (1)

Results publications

PMID 19874198, PMID 20740685, PMID 21147688, PMID 22777865, PMID 24064689, PMID 26879200

NIH funding

2008 (1)